Duke's leukemia and lymphoma programs combine state-of-the-art, compassionate medical care with innovative science to improve outcomes for patients battling leukemias, lymphomas, myelomas, and other blood- and lymphoid-related cancers, including many rare cancers.

The program’s highly experienced team of caregivers provides individualized, hands-on medical attention to each of the nearly 1,000 patients we see each year.

Our nationally reputed medical oncologists, surgeons, radiation oncologists, and stem and marrow transplantation specialists work together to plan a comprehensive treatment strategy for each patient, drawing on the most effective therapies -- including many that have been developed and refined right here at Duke.

About Leukemia and Lymphoma

Currently, there are approximately 140,000 lymphoma cases and 75,000 leukemia cases in the United States. The five-year survival rate for lymphomas ranges from 25 to 65 percent.

The most common types of adult leukemia are acute myeloid leukemia and chronic lymphocytic leukemia. Five-year survival rates for leukemia patients vary depending on risk factors but have generally improved since the 1970s with many patients now cured.